15,260 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC purchased a new position in shares of Exact Sciences Co. (NASDAQ:EXAS) in the 3rd quarter, Holdings Channel reports. The firm purchased 15,260 shares of the medical research company’s stock, valued at approximately $1,040,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Exact Sciences by 16.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 89,196 shares of the medical research company’s stock worth $6,160,000 after buying an additional 12,349 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its holdings in shares of Exact Sciences by 5.3% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 207,364 shares of the medical research company’s stock worth $14,361,000 after purchasing an additional 10,356 shares during the period. Profund Advisors LLC lifted its stake in shares of Exact Sciences by 239.8% in the 2nd quarter. Profund Advisors LLC now owns 78,589 shares of the medical research company’s stock valued at $3,320,000 after purchasing an additional 55,459 shares in the last quarter. William Blair Investment Management LLC purchased a new stake in shares of Exact Sciences during the 2nd quarter worth about $163,896,000. Finally, Swedbank AB acquired a new stake in Exact Sciences during the 1st quarter worth approximately $2,719,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Price Performance

Shares of EXAS stock opened at $51.48 on Monday. The firm has a fifty day moving average of $66.76 and a two-hundred day moving average of $56.46. The firm has a market cap of $9.53 billion, a P/E ratio of -44.00 and a beta of 1.27. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.98.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The firm had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. The company’s revenue for the quarter was up 12.8% compared to the same quarter last year. As a group, research analysts anticipate that Exact Sciences Co. will post -1.02 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on EXAS shares. Craig Hallum reduced their price target on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Stifel Nicolaus reduced their target price on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Jefferies Financial Group increased their price target on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. BTIG Research reduced their price objective on Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, TD Cowen lowered their target price on Exact Sciences from $90.00 to $82.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $74.47.

Insider Activity

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $70.00, for a total transaction of $65,030.00. Following the sale, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at approximately $893,060. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.36% of the company’s stock.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.